222 related articles for article (PubMed ID: 31553932)
1. Design and synthesis of parthenolide and 5-fluorouracil conjugates as potential anticancer agents against drug resistant hepatocellular carcinoma.
Ding Y; Li S; Ge W; Liu Z; Zhang X; Wang M; Chen T; Chen Y; Zhang Q
Eur J Med Chem; 2019 Dec; 183():111706. PubMed ID: 31553932
[TBL] [Abstract][Full Text] [Related]
2. Design and synthesis of parthenolide-SAHA hybrids for intervention of drug-resistant acute myeloid leukemia.
Ge W; Liu Z; Sun Y; Wang T; Guo H; Chen X; Li S; Wang M; Chen Y; Ding Y; Zhang Q
Bioorg Chem; 2019 Jun; 87():699-713. PubMed ID: 30953889
[TBL] [Abstract][Full Text] [Related]
3. Reversing resistance of multidrug-resistant hepatic carcinoma cells with parthenolide.
Liu D; Liu Y; Liu M; Ran L; Li Y
Future Oncol; 2013 Apr; 9(4):595-604. PubMed ID: 23560381
[TBL] [Abstract][Full Text] [Related]
4. MEL-pep, an analog of melittin, disrupts cell membranes and reverses 5-fluorouracil resistance in human hepatocellular carcinoma cells.
Ke M; Dong J; Wang Y; Zhang J; Zhang M; Wu Z; Lv Y; Wu R
Int J Biochem Cell Biol; 2018 Aug; 101():39-48. PubMed ID: 29800725
[TBL] [Abstract][Full Text] [Related]
5. Synthesis and biological evaluation of novel podophyllotoxin-NSAIDs conjugates as multifunctional anti-MDR agents against resistant human hepatocellular carcinoma Bel-7402/5-FU cells.
Zhang L; Liu L; Zheng C; Wang Y; Nie X; Shi D; Chen Y; Wei G; Wang J
Eur J Med Chem; 2017 May; 131():81-91. PubMed ID: 28301815
[TBL] [Abstract][Full Text] [Related]
6. Design, synthesis and biological evaluation of hybrid of ubenimex-fluorouracil for hepatocellular carcinoma therapy.
Yue K; Hou X; Jia G; Zhang L; Zhang J; Tan L; Wang X; Zhang Z; Li P; Xu W; Li X; Jiang Y
Bioorg Chem; 2021 Nov; 116():105343. PubMed ID: 34544027
[TBL] [Abstract][Full Text] [Related]
7. MiR-27a modulates the MDR1/P-glycoprotein expression by inhibiting FZD7/β-catenin pathway in hepatocellular carcinoma cells.
Chen Z; Ma T; Huang C; Zhang L; Lv X; Xu T; Hu T; Li J
Cell Signal; 2013 Dec; 25(12):2693-701. PubMed ID: 24018051
[TBL] [Abstract][Full Text] [Related]
8. Quantitative proteomic and phosphoproteomic studies reveal novel 5-fluorouracil resistant targets in hepatocellular carcinoma.
Liu Z; Wang Y; Yao Y; Fang Z; Miao QR; Ye M
J Proteomics; 2019 Sep; 208():103501. PubMed ID: 31454556
[TBL] [Abstract][Full Text] [Related]
9. Comparison of the multi-drug resistant human hepatocellular carcinoma cell line Bel-7402/ADM model established by three methods.
Zhong X; Xiong M; Meng X; Gong R
J Exp Clin Cancer Res; 2010 Aug; 29(1):115. PubMed ID: 20727186
[TBL] [Abstract][Full Text] [Related]
10. Synthesis and biological evaluation of phenyl substituted polyoxygenated xanthone derivatives as anti-hepatoma agents.
Dai M; Yuan X; Kang J; Zhu ZJ; Yue RC; Yuan H; Chen BY; Zhang WD; Liu RH; Sun QY
Eur J Med Chem; 2013 Nov; 69():159-66. PubMed ID: 24013415
[TBL] [Abstract][Full Text] [Related]
11. Characterization and resistance mechanisms of a 5-fluorouracil- resistant hepatocellular carcinoma cell line.
Gu W; Fang FF; Li B; Cheng BB; Ling CQ
Asian Pac J Cancer Prev; 2012; 13(9):4807-14. PubMed ID: 23167424
[TBL] [Abstract][Full Text] [Related]
12. Mechanism of 5-fluorouracil required resistance in human hepatocellular carcinoma cell line Bel(7402).
Jin J; Huang M; Wei HL; Liu GT
World J Gastroenterol; 2002 Dec; 8(6):1029-34. PubMed ID: 12439919
[TBL] [Abstract][Full Text] [Related]
13. TFPI-2 downregulates multidrug resistance protein in 5-FU-resistant human hepatocellular carcinoma BEL-7402/5-FU cells.
Lu F; Hou YQ; Song Y; Yuan ZJ
Anat Rec (Hoboken); 2013 Jan; 296(1):56-63. PubMed ID: 23125179
[TBL] [Abstract][Full Text] [Related]
14. Hypoxia induces universal but differential drug resistance and impairs anticancer mechanisms of 5-fluorouracil in hepatoma cells.
Li JQ; Wu X; Gan L; Yang XL; Miao ZH
Acta Pharmacol Sin; 2017 Dec; 38(12):1642-1654. PubMed ID: 28713155
[TBL] [Abstract][Full Text] [Related]
15. The Antitumor Effects of Britanin on Hepatocellular Carcinoma Cells and its Real-Time Evaluation by In Vivo Bioluminescence Imaging.
Li H; Du G; Yang L; Pang L; Zhan Y
Anticancer Agents Med Chem; 2020; 20(9):1147-1156. PubMed ID: 32106805
[TBL] [Abstract][Full Text] [Related]
16. Reversal effect of bufalin on multidrug resistance in human hepatocellular carcinoma BEL-7402/5-FU cells.
Gu W; Liu L; Fang FF; Huang F; Cheng BB; Li B
Oncol Rep; 2014 Jan; 31(1):216-22. PubMed ID: 24173654
[TBL] [Abstract][Full Text] [Related]
17. Discovery of novel isatin-dehydroepiandrosterone conjugates as potential anticancer agents.
Ke S; Shi L; Yang Z
Bioorg Med Chem Lett; 2015 Oct; 25(20):4628-31. PubMed ID: 26320625
[TBL] [Abstract][Full Text] [Related]
18. Discovery of penipanoid C-inspired 2-(3,4,5-trimethoxybenzoyl)quinazolin-4(3H)-one derivatives as potential anticancer agents by inhibiting cell proliferation and inducing apoptosis in hepatocellular carcinoma cells.
Wang CJ; Guo X; Zhai RQ; Sun C; Xiao G; Chen J; Wei MY; Shao CL; Gu Y
Eur J Med Chem; 2021 Nov; 224():113671. PubMed ID: 34237623
[TBL] [Abstract][Full Text] [Related]
19. Annonaceous acetogenins reverses drug resistance of human hepatocellular carcinoma BEL-7402/5-FU and HepG2/ADM cell lines.
Qian JQ; Sun P; Pan ZY; Fang ZZ
Int J Clin Exp Pathol; 2015; 8(9):11934-44. PubMed ID: 26617951
[TBL] [Abstract][Full Text] [Related]
20. Design, synthesis and biological evaluation of novel 1,3,4-trisubstituted pyrazole derivatives as potential chemotherapeutic agents for hepatocellular carcinoma.
Harras MF; Sabour R
Bioorg Chem; 2018 Aug; 78():149-157. PubMed ID: 29567429
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
